In CD34-positive AML, the leukemic stem cell has been recognized as CD38 negative. This CD34+CD38− population survives chemotherapy and is most probable the cause of minimal residual disease (MRD).

"Because AML stem cells are mainly CD38-negative, however, scientists have not prioritized CD38 as a therapeutic target for relapsed acute myeloid leukemia." In the current study, CD38-BIONIC ...

Data for CD34+CD38− bone marrow cells, promyelocytes, neutrophils, and monocytes from three healthy volunteers are plotted to the left of the data for 192 AML samples in each panel. CpG islands ...

HSPCs polarize in contact with bone marrow stromal cells constituting their niche. This study analyses the polarity of ...

A cohort of 73 AML patient samples were sorted based on CD34 and CD38 expression, in which each fraction was functionally assessed for ability to engraft NSG mice. Single cell assays captured ...

BN-CD38 eradicates acute myeloid leukemia (AML) by inducing the expression of its own therapeutic target and by expanding and redirecting autologous T-cells against AML blasts and leukemia stem cells.

While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a thorough evaluation of the data, the market landscape, and Genmab’s rigorous portfolio ...

However, IFNy also stimulates CD38, a protein that suppresses the ... and treatment relapse common to patients with acute myeloid leukemia (AML), the therapy method could provide a less toxic ...

Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 Genmab will not pursue further clinical ...